A Brisbane biotech company, led by award-winning immunologist Ian Frazer, has created an anti-inflammatory drug, which is being trialled as a potential treatment for severely-ill COVID-19 patients in the United States.
- The drug is being trailed on 300 people in the US, with results expected in about six months
- If successful, drug IC14 could become part of routine care to treat COVID-19 patients with severe infection
- Professor Ian Frazer says the drug could provide a new way to treat people dying from COVID-19
The new drug is not a vaccine but rather a treatment being trialled, and if proven successful, could become part of routine care in serious cases to prevent people dying from the virus.
Professor Frazer, who was the…